The company had provided only non-GLP services focused on early stage research and discovery.
Aragen Bioscience specializes in recombinant cell line and hybridoma development, cell culture and protein purification process development and production, primary and immortalized cell-based assays, in vivo models of human disease and custom immunological services.
Aragen president and CEO Rick Srigley said with the implementation of GLP services in their rodent facility, they can now offer their clients a transition from early stage research studies into the GLP compliant studies necessary to support IND submissions to the FDA.
Aragen’s intends to expand its services to include GLP compliant cell-based assays in the near future.